AU · rank #3 · 2026-10-21
GRAL
NASDAQ · $5.47B (USD)
The exact numbers the algorithm saw.
| Composite score Z-score blend of all factors below. | 2.764 |
|---|---|
| EPS revisions (30d) Change in consensus EPS estimate over the past 30 days ($/share). | +$0.69 |
| Net revisions (30d) Number of analysts revising upward minus downward. | 1 |
| Insider signal (90d) $0 across 0 unique buyers. | -0.206 |
| Analyst upside Consensus target $131.30 | +7.3% |
| Momentum acceleration 3-month minus 12-month momentum. | +62.43% |
| Analyst rating 5 = Strong Buy, 1 = Strong Sell. | 3.91 |
| Gross margin TTM | +49.7% |
| 52w high | $166.48 |
| Market cap (USD) | $5.47B |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
GRAIL, LLC is a healthcare diagnostics company commercializing Galleri, a liquid biopsy blood test designed to detect cancer signals across more than 50 cancer types.
Rationale
The analyst upside signal is validated by unanimous positive EPS revisions, 7 price target raises over the past 30 days, a 44.9% Q2 earnings beat, and a major regulatory catalyst in the favorable September 2026 FDA advisory committee vote.
Material risks
- 1The FDA could delay or reject final Premarket Approval (PMA) or demand extensive long-term outcome trials before granting full commercial clearance.
- 2Severe ongoing cash burn ($110.2 million Q2 net loss and negative gross profit) creates substantial financial downside if broad insurance reimbursement is delayed.
AI verdict council
Each pick is reviewed independently by 3 models before any order. 2 of 3 voted to proceed.